An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer (CRPC).

Carmel Pezaro, Mark Rosenthal, Howard Gurney, Ian Davis, Craig R Underhill, Michael J Boyer, Dusan Kotasek, Benjamin Solomon, Guy Toner

Research output: Contribution to journalArticleResearchpeer-review

43 Citations (Scopus)
Original languageEnglish
Pages (from-to)338 - 341
Number of pages4
JournalAmerican Journal of Clinical Oncology
Issue number4
Publication statusPublished - 2009

Cite this